CONF-2025-ACC-STRIDE-LateBreaker — ACC.25 Late-Breaker: STRIDE (Semaglutide + PAD)

[DRAFT — authored 2026-04-19. Conference context web-verified via ACC, Novo Nordisk press release, and coverage outlets 2026-04-19.]

Meeting Metadata

• Conference: American College of Cardiology Annual Scientific Session 2025 (ACC.25)
• Dates: March 29-31, 2025 (STRIDE presented March 29, 2025)
• Location: Chicago, IL, USA
• Session type: Late-Breaking Clinical Trial session

Presentation

• Presenter: Marc P. Bonaca, MD, MPH
• Study: STRIDE — Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes
• Sponsor: Novo Nordisk
• Simultaneous publication: The Lancet

Key Findings as Presented

• Design: Double-blind Phase 3b, 112 outpatient clinics in North America, Asia, Europe, October 2020 – July 2024
• n=792 participants (median age 68, 25% women, 68% White) with T2D and PAD with intermittent claudication
• Randomized 1:1 to semaglutide 1.0 mg weekly SC (n=396) or placebo (n=396), treatment to 52 weeks
• Primary outcome — maximum walking distance: median improvement 26 m; mean improvement 40 m; 13% statistically significant improvement at 1 year vs placebo
• Improvements in WIQ (Walking Impairment Questionnaire) subscales, SF-36 physical function, EQ-5D
• Median BMI 28.6; weak correlation between weight loss and walking outcomes — authors note benefit may be via direct vascular effect rather than weight-loss-mediated

Cross-Link to Full Publication

• PMID-40169145 – STRIDE Semaglutide PAD — Bonaca MP, Catarig AM, Houlind K, et al. Lancet. 2025;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4.

This CONF note captures the conference-abstract presentation context. Full evidence is in the PMID note.

Relevance to Module 5

• Lesson 5.2 (Semaglutide Deep Dive — Section 6 Expanded Evidence Base) — STRIDE PAD evidence block
• Semaglutide profile Clinical Applications (PAD indication) and Evidence Base table

Sources

• ACC Latest in Cardiology — STRIDE Trial page
• Novo Nordisk press release (March 29, 2025): "Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial"
• HCPLive, AJMC, Pharmacy Times, Cardiovascular Business late-breaking coverage

Orchestrator Notes

• CONF note cross-linked to full-publication PMID — not a stand-alone orphan.
• Verified 2026-04-19 via ACC official page.

Tags

#conference #acc #acc25 #late-breaker #stride #semaglutide #peripheral-artery-disease #pad